ArticleThe clinical respiratory journal2025
Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United States.
Article in The clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough patients with bronchiectasis often have comorbidities, the impact of bronchiectasis on managing these is unknown. This study assessed the incremental burden of managing chronic obstructive pulmonary disease (COPD), asthma, and rheumatoid arthritis in patients with bronchiectasis.
methodsThis retrospective cohort study using Merative MarketScan US claims data included patients with a COPD, asthma, or rheumatoid arthritis diagnosis between January 2017 and December 2021. Within these cohorts, patients with a bronchiectasis diagnosis (excluding cystic fibrosis) were compared with nonbronchiectasis controls following 1:1 propensity score matching (1:2 for rheumatoid arthritis). Comorbid disease-specific inpatient, outpatient, and emergency room (ER) visits and direct medical costs were reported.
resultsAfter matching, 4291 patients with COPD, 2460 with asthma, and 566 with rheumatoid arthritis, all with bronchiectasis, and the corresponding controls, were included. For patients with COPD, proportions with COPD-related outpatient (66.5% vs. 56.8%), ER (7.5% vs. 5.8%), and inpatient visits (4.5% vs. 3.1%), as well as respiratory-related ($11 054 vs. $6961) and disease-specific ($1384 vs. $1107) costs were significantly higher in the bronchiectasis cohort (vs. control cohort). For patients with asthma, asthma-related outpatient visits (52.0% vs. 41.1%), respiratory-related ($10 327 vs. $5458), and disease-specific ($489 vs. $221) costs were significantly higher in the bronchiectasis cohort. For patients with rheumatoid arthritis, rheumatoid arthritis-specific PPPY outpatient (5.1 vs. 3.9) and specialist visits (3.5 vs. 2.5), and disease-specific ($4820 vs. $2592) costs were significantly higher in the bronchiectasis cohort (p < 0.05 for all comparisons).
conclusionsBronchiectasis is associated with higher comorbid disease-related healthcare resource utilization and costs and complicates the management of comorbid conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.